98%
921
2 minutes
20
This study aimed to evaluate the relationship between the consumption of different dietary fatty acids and the risk of bladder cancer. A quantitative analysis was conducted using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which included 101,731 participants. The Cox proportional hazards model was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for bladder cancer risk in relation to dietary fatty acid intake. During a median follow-up of 11.3 years, 861 bladder cancer cases were identified. After fully adjusting for potential confounders in a multivariate Cox regression model, no significant association was found between dietary fatty acid consumption and bladder cancer risk. Subgroup analysis revealed significant interactions with gender ( < 0.001) and smoking status ( < 0.001). Gender-specific analysis showed that a higher intake of monounsaturated fatty acids (MUFAs) was linked to a reduced risk of bladder cancer in females (HR: 0.62; 95% CI: 0.39-0.99, -trend = 0.028). However, restricted cubic spline analysis revealed no linear relationship between MUFA intake and bladder cancer risk in the overall group or gender-specific subgroups. The association between dietary fatty acids and bladder cancer risk is influenced by factors like gender and smoking status. In females, moderate MUFA intake may reduce bladder cancer risk, but higher intake does not provide additional benefits.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/01635581.2025.2492138 | DOI Listing |
J Pediatr Hematol Oncol
September 2025
Department of Pediatric, The University of Jordan.
Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.
View Article and Find Full Text PDFPediatr Surg Int
September 2025
Pediatric Surgery Unit, Department of Women's and Children's Health, University of Padua, Via Nicolò Giustiniani, 35100, Padua, Italy.
Introduction: Brachytherapy has been used for the multimodal treatment of pediatric bladder-prostate rhabdomyosarcoma in the last two decades. The aim of this systematic review is to gather the current evidence about this innovative technique with a special focus on long-term outcomes.
Methods: According to PRISMA criteria, PubMed, Scopus, and Web of Science were searched for papers published between 2000 and 2022.
J Cancer Res Clin Oncol
September 2025
Cancer Treatment and Nuclear Cardiology Department, Al Azhar University, Cairo, Egypt.
Background: High-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative.
View Article and Find Full Text PDF